Pneumonia
Conditions
Keywords
Nebulization, ceftazidime, amikacin, pneumonia, Pseudomonas aeruginosa, mechanical ventilation, Ventilator-associated pneumonia, treatment
Brief summary
Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.
Interventions
DRUGceftazidime and amikacin
Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
Sponsors
Groupe Hospitalier Pitie-Salpetriere
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female \>18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa * Written informed consent provided by the relatives
Exclusion criteria
* Pseudomonas aeruginosa resistant to ceftazidime and amikacin * Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment * Severe septic shock and severe hypoxemia * Allergy to ceftazidime or amikacin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bacterial killing | 14 days |
Secondary
| Measure | Time frame |
|---|---|
| Changes of lung aeration | 8 days |
Countries
France
Outcome results
None listed